Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: A systematic genetic study

The Lancet Oncology

Volumn 16, Issue 16, 2015, Pages 1659-1666

  Moriyama, Takaya ^a,b   Metzger, Monika L ^a   Wu, Gang ^a   Nishii, Rina ^a,c   Qian, Maoxiang ^a   Devidas, Meenakshi ^d   Yang, Wenjian ^a   Cheng, Cheng ^a   Cao, Xueyuan ^a   Quinn, Emily ^a   Raimondi, Susana ^a   Gastier Foster, Julie M ^e   Raetz, Elizabeth ^f   Larsen, Eric ^g   Martin, Paul L ^h   Bowman, W Paul ⁱ   Winick, Naomi ^j   Komada, Yoshihiro ^b   Wang, Shuoguo ^a   Edmonson, Michael ^a   Xu, Heng ^k   Mardis, Elaine ^l   Fulton, Robert ^l   Pui, Ching Hon ^a   Mullighan, Charles ^a   Evans, William E ^a   Zhang, Jinghui ^a   Hunger, Stephen P ^m   Relling, Mary V ^a   Nichols, Kim E ^a   Loh, Mignon L ⁿ   Yang, Jun J ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g Duke University ^*  (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ University of Texas Southwestern Medical Center ^*  (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k SICHUAN UNIVERSITY   (China)

^l WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR ETV6; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR ETS; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER RISK; CAUSAL ATTRIBUTION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; ETV6 GENE; EXOME; EXON; FEMALE; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; AGE; BIOLOGY; CASE CONTROL STUDY; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC DATABASE; GENETICS; KARYOTYPING; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; EXOME; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; KARYOTYPING; MALE; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84951304790     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00369-1     Document Type: Article

References (55)

1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011, 29:551-565.
2. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012, 30:1663-1669.
3. Moorman AV, Enshaei A, Schwab C, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014, 124:1434-1444.
4. Stanulla M, Schrappe M Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 2009, 46:52-63.
5. Kinlen L Childhood leukaemia, nuclear sites, and population mixing. Br J Cancer 2011, 104:12-18.
6. Swaminathan S, Klemm L, Park E, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol 2015, 16:766-774.
7. Greaves M Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006, 6:193-203.
8. Kharazmi E, da Silva Filho MI, Pukkala E, Sundquist K, Thomsen H, Hemminki K Familial risks for childhood acute lymphocytic leukaemia in Sweden and Finland: far exceeding the effects of known germline variants. Br J Cancer 2012, 159:585-588.
9. Hemminki K, Jiang Y Risks among siblings and twins for childhood acute lymphoid leukaemia: results from the Swedish Family-Cancer Database. Leukemia 2002, 16:297-298.
10. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 2009, 41:1006-1010.
11. Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 2009, 41:1001-1005.
12. Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 2013, 45:1494-1498.
13. Migliorini G, Fiege B, Hosking FJ, et al. Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood 2013, 122:3298-3307.
14. Xu H, Zhang H, Yang W, et al. Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nat Commun 2015, 6:7553.
15. Sherborne AL, Hosking FJ, Prasad RB, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 2010, 42:492-494.
16. Xu H, Yang W, Perez-Andreu V, et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst 2013, 105:733-742.
17. Ellinghaus E, Stanulla M, Richter G, et al. Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia 2012, 26:902-909.
18. Hasle H, Clemmensen IH, Mikkelsen M Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000, 355:165-169.
19. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41:1243-1246.
20. Li Y, Schwab C, Ryan SL, et al. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 2014, 508:98-102.
21. Shah S, Schrader KA, Waanders E, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 2013, 45:1226-1231.
22. Perez-Garcia A, Ambesi-Impiombato A, Hadler M, et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood 2013, 122:2425-2432.
23. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013, 45:242-252.
24. Wang LC, Swat W, Fujiwara Y, et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev 1998, 12:2392-2402.
25. Kar A, Gutierrez-Hartmann A Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Crit Rev Biochem Mol Biol 2013, 48:522-543.
26. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
27. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med 2011, 208:2571-2579.
28. Bhojwani D, Pei D, Sandlund JT, et al. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2012, 26:265-270.
29. Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet 2015, 47:180-185.
30. Noetzli L, Lo RW, Lee-Sherick AB, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet 2015, 47:535-538.
31. Topka S, Vijai J, Walsh MF, et al. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLoS Genet 2015, 11:e1005262.
32. Pui CH, Mahmoud HH, Rivera GK, Hancock ML, Sandlund JT, Behm FG, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998, 92:411-415.
33. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004, 104:2690-2696.
34. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009, 360:2730-2741.
35. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008, 111:5477-5485.
36. Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood 2015, 126:964-971.
37. Tennessen JA, Bigham AW, O'Connor TD, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012, 337:64-69.
38. Pritchard JK, Stephens M, Donnelly P Inference of population structure using multilocus genotype data. Genetics 2000, 155:945-959.
39. Yang JJ, Cheng C, Devidas M, et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 2011, 43:237-241.
40. Fernandez CA, Smith C, Yang W, et al. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood 2015, 126:69-75.
41. Edmonson MN, Zhang J, Yan C, Finney RP, Meerzaman DM, Buetow KH Bambino: a variant detector and alignment viewer for next-generation sequencing data in the SAM/BAM format. Bioinformatics 2011, 27:865-866.
42. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011, 43:491-498.
43. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015, 43(database issue):D805-D811.
44. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013, 15:565-574.
45. Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 2014, 133:1-9.
46. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014, 42(database issue):D980-D985.
47. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014, 46:310-315.
48. Fine JP, Gray RJ A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
49. De S, Chan AC, Coyne HJ, et al. Steric mechanism of auto-inhibitory regulation of specific and non-specific DNA binding by the ETS transcriptional repressor ETV6. J Mol Biol 2014, 426:1390-1406.
50. Moriyama T, Relling MV, Yang JJ Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood 2015, 125:3988-3995.
51. Papaemmanuil E, Rapado I, Li Y, et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet 2014, 46:116-125.
52. Alpar D, Wren D, Ermini L, et al. Clonal origins of ETV6-RUNX1(+) acute lymphoblastic leukemia: studies in monozygotic twins. Leukemia 2015, 29:839-846.
53. Greaves MF, Wiemels J Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003, 3:639-649.
54. Guidez F, Petrie K, Ford AM, et al. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood 2000, 96:2557-2561.
55. Hock H, Meade E, Medeiros S, et al. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev 2004, 18:2336-2341.